Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Extension Study of Osivelotor in Sickle Cell Disease
NCT05632354Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Jan 2023
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of osivelotor in sickle cell disease (SCD), sponsored by Pfizer. Started Jan 2023; status: terminated.
02
Drugs
osivelotor
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT05632354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05632354.